Akebia Therapeutics, a biotech developing a breakthrough anemia treatment with a once-daily oral dose, raised $100 million in an upsized IPO by offering 5.9 million shares at $17, the high end of the range of $14 to $17. The company had originally planned to offer 4.9 million shares. Akebia Therapeutics plans to list on the NASDAQ under the symbol AKBA. Akebia Therapeutics initially filed confidentially on 12/20/2013. Morgan Stanley, Credit Suisse and UBS Investment Bank acted as lead managers on the deal.
